Informação sobre produto
Nome:
Bucindolol
Sinónimos:
- 2-[2-Hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]benzonitrile
- 2-(2-hydroxy-3-{[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino}propoxy)benzonitrile hydrochloride (1:1)
- <span class="text-smallcaps">DL</span>-Bucindolol hydrochloride
- Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]-, hydrochloride (1:1)
- Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]-, monohydrochloride
- Bucindolol hydrochloride
- Mj-13105-1
- o-[2-Hydroxy-3-[(2-indol-3-yl-1,1-dimethylethyl)amino]propoxy]benzonitrile monohydrochloride
Descrição:
Bucindolol is a beta-blocker that has been shown to have cardiac, receptor activity, atrial, and myocardial infarct properties. It also has natriuretic peptide levels and biological sample properties. Bucindolol binds to beta-adrenergic receptors in the heart, which leads to decreased heart rate, increased systolic pressure, and relaxation of the papillary muscles. This drug has also been shown to inhibit the production of proprotein convertase subtilisin/kexin type 9 (PCSK9) in vitro.
Aviso:
Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Marca:
Biosynth
Armazenamento a longo prazo:
Notas:
Propriedades químicas
Peso molecular:
363.45 g/mol
Fórmula:
C22H25N3O2
Pureza:
Min. 95%
InChI:
InChI=1S/C22H28N2O2/c1-16-8-4-7-11-21(16)26-15-18(25)14-24-22(2,3)12-17-13-23-20-10-6-5-9-19(17)20/h4-11,13,18,23-25H,12,14-15H2,1-3H3
Chave InChI:
InChIKey=LBQVRBUQVRRHIB-UHFFFAOYSA-N
SMILES:
CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N
MDL:
Ponto de fusão:
Ponto de ebulição:
Ponto de inflamação:
Densidade:
Concentração:
EINECS:
Merck:
Código HS:
